论文部分内容阅读
目的观察国产长春瑞滨(NVB)联合顺铂(DDP)治疗晚期非小细胞肺癌的疗效及毒副反应。方法52例晚期NSCLC中男37例,女15例;鳞癌35例,腺癌17例;ⅢA期9例,ⅢB期15例,Ⅳ期28例;初治42例,复治10例;采用长春瑞滨(NVB)25mg/m2第1,8天静滴;顺铂(DDP)25mg/m2,第1～3天静滴,21d为一周期。结果完全缓解(CR)1例,部分缓解(PR)20例,稳定(SD)27例,进展(PD)4例,总有效率为40.4%。中位疾病进展时间5.6个月,中位生存期11个月,一年生存率46.2%。主要毒副反应为Ⅰ、Ⅱ度骨髓抑制53.8%(28/52),恶心、呕吐发生率为30.8%,其次为静脉炎,发生率11.5%。结论NP方案治疗晚期NSCLC疗效确切,毒副反应可耐受,价格相对便宜,为符合我国国情的治疗晚期非小细胞肺癌的方案。
Objective To observe the efficacy and side effects of domestic vinorelbine (NVB) combined with cisplatin (DDP) in the treatment of advanced non-small cell lung cancer. Methods Fifty-two patients with advanced NSCLC had 37 males and 15 females, 35 with squamous cell carcinoma, 17 with adenocarcinoma, 9 with stage ⅢA, 15 with stage ⅢB, 28 with stage Ⅳ, and 42 with initial treatment and 10 with re-treatment. Vinorelbine (NVB) 25mg / m2 on the first and eighth days of intravenous infusion; cisplatin (DDP) 25mg / m2, the first 3 days intravenous infusion, 21d for a cycle. Results The complete remission (CR) in 1 case, partial remission (PR) in 20 cases, stable (SD) in 27 cases and progression (PD) in 4 cases, the total effective rate was 40.4%. The median time to progression was 5.6 months, with a median survival of 11 months and a one-year survival of 46.2%. The main side effects were grade I and II myelosuppression 53.8% (28/52), nausea and vomiting 30.8%, followed by phlebitis with a rate of 11.5%. Conclusion NP regimen is effective in treating advanced non-small cell lung cancer (NSCLC), and its toxicity and side effects are tolerable and relatively cheap. It is a regimen for treating advanced non-small cell lung cancer in line with China’s national conditions.